The Internal Revenue Service (IRS) has issued temporary regulations for imposing billions of dollars of branded prescription drug fees on drugmakers under the Patient Protection and Affordable Care Act, but it was not immediately clear whether the complex rules resolved earlier industry concerns that included the data and process used to calculate fees for individual companies.